News
Vertex is laying off 125 employees in Rhode Island and consolidating offices, following the discontinuation of a Type 1 ...
Vertex Pharmaceuticals is laying off workers and consolidating its real estate footprint in Rhode Island after ending a ...
GSK GSK0.87%increase; green up pointing triangle will acquire a liver-disease treatment from Boston Pharmaceuticals for up to $2 billion as it seeks to boost its pipeline of new drugs. The British ...
Hosted on MSN1mon
GSK to buy phase III-ready drug efimosfermin from Boston Pharmaceuticals for as much as $2BBritish pharmaceutical company GSK (NYSE:GSK) to acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa, for as much as $2 billion in cash. Under the agreement, GSK will pay $1.2 billion ...
Under the agreement, GSK will acquire BP Asset IX, a subsidiary of Boston Pharmaceuticals, for up to $2 billion in total cash consideration, including $1.2 billion upfront and up to $800 million in ...
Scouting America is proud to announce that Bob Rivers, Executive Chair and Chair of the… Basil Tree Catering is a certified Woman Owned and LGBT Owned Business ...
Company to meet with prospective partners as it accelerates toward IND submission for Telomir-1, with plans to begin human ...
MIAMI, FL / ACCESS Newswire / May 28, 2025 / MIRA Pharmaceuticals ... taking place in Boston, MA from June 16-19, 2025. The Company has a full schedule of BIO One-on-One Partnering™ meetings ...
The treatment, made by Boston Pharmaceuticals, is ready to enter the last stage of clinical tests, the UK drugmaker said Wednesday. The medicine could become a blockbuster, according to analysts ...
The company will engage in BIO One-on-One Partnering™ meetings as it advances Phase 1 for Ketamir-2, prepares Phase IIa study in neuropathic pain, and finalizes filings for SKNY acquisition.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results